ANDAs To Include Six Months Of Stability Test Data Under FDA Draft Guidance
Executive Summary
The agency advises sponsors to follow the stability testing recommendations in the International Conference on Harmonization guidances; FDA had considered requiring 12 months of data.
You may also be interested in...
Generics Joining The 12-Month Stability Data Club, But “When?” Is Big Question
Generic drug sponsors will need to submit six-month and 12-month stability data for their ANDAs under draft guidance being developed by the Office of Generic Drugs.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.